中文名称 ：卡博替x.
中文别名：
卡博替x;卡博替x;Cabozantinib (XL184, BMS-907351) 抑制剂;Cabozantinib标准品;N-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-N-(4-氟苯基)环丙烷-1,1-二羧酰胺;XL184（博卡替x）;XL184（卡博替x）靶向药;XL184（卡博替x）粉末;XL184（卡博替x）固体状;XL184,卡博替x;卡巴唑替x;卡博替x XL184;卡博替x cabozantinib;卡博替x（CABOZANTINIB）;卡博替x苹果酸盐;卡博替x中间体;科研实验XL184（卡博替x）;临床实验XL184;苹果酸盐;苹果酸盐Cabozantinib,XL-184;医药级XL184（卡博替x）;N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(4-氟苯基)-1,1-环丙烷二甲酰胺;博卡替x;卡赞替x;苹果酸盐CABOZANTINIB杀菌原材料;苹果酸盐CABXL-184;鑫源顺 卡博替x;卡波替x杂质
英文名称：Cabozantinib
英文别名：
XL184;Cabozantinib (XL184, BMS-907351);1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-;1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;C28H24FN3O5;Cabozantinib;Cabozantinib (XL184,BMS 907351,Cometriq®);Cabozantinib S-malate;Cabozantinib, XL184;N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;XL-180;XL-184;XL184 Cabozantinib;[14C]-Cabozantinib;BMS907351;BMS-907351;Cometriq;cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide;N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;Cabozantinib Impurity
Cas No.：849217-68-1
分子式：C28H24FN3O5
分子量：501.51
包装储存：
4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

生物活性 ：
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
性状：Solid

运输条件 ：Room temperature or refrigerated transportation.
储存方式：
4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

ClinicalTrial
参考文献：
[1]. Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.  [Information]

[2]. You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.  [Information]

[3]. Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398.  

本文引用：http://www.med-life.cn/
Medlife，致力于提供高品质、高性价比小分子化合物的产品。
Medlife小分子化合物大量库存，提供超过2万种的抑制剂、激动剂、拮抗剂等产品，是药物及疾病研究的重要原料供应商。